The stock was last quoted at $21.05, up 17%, on volume of nearly 30,000, according to Nasdaq.com. Based on a regular session close at $17.98, the shares were down about 49% so far in 2010. The stock has seen a slight bounce since scraping its 52-week low of $15.50 on June 24 but it's still off 54% since hitting its high for the year of $39 on May 5. The company's market capitalization was around $316 million. Genoptix provides diagnostic test services related to hematology and oncology. The company reported its fiscal third-quarter results on Nov. 4, posting a profit of $4.4 million, or 24 cents a share, for the three months ended Sept. 30 on revenue of $49.5 million. The EPS performance was 11% ahead of Wall Street's consensus estimate for earnings of 22 cents a share in the September period.